Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Register now and meet us in Madrid to gain unique insights into the latest data in oncology today
Meet Asian and international key opinion leaders in the entire field of oncology on 1-3 December in Singapore and discover the latest breakthroughs in cancer research and treatment.
Enhance your knowledge and advance the treatment and management of cancers of the GI tract. Join us in Barcelona on 28 June – 1 July.
Discover the latest advancements and explore the potential of immuno-oncology in treating colorectal cancer
The best practice recommendations for the treatment of this tumour type are just one click away – Join and get your questions answered
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Findings from the pivotal HERIZON-BTC-01 study
ESMO would like to thank the Hellenic Society of Medical Oncology (HeSMO) for providing translation in the Greek language
ESMO would like to thank the Hellenic Society of Medical Oncology (HeSMO) for providing translation in the Greek language
Findings from the TALAPRO-2 study
ESMO would like to thank the Hellenic Society of Medical Oncology (HeSMO) for providing translation in the Greek language
Evidence for efficacy is based on the results from the PROpel study
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Findings from the the window-of-opportunity TOT-HER3 study
Findings from the pivotal HERIZON-BTC-01 study
Findings from the TALAPRO-2 study
Evidence for efficacy is based on the results from the PROpel study
Findings from the the window-of-opportunity TOT-HER3 study
Findings from the CAPItello-291 study
The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence
Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
The new online tool comes in an interactive, concise, and updatable visual format to support practicing oncologists in the rapidly evolving medical field
The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
ESMO launched the ESMO Living Guidelines, a new tool designed to make the ESMO Clinical Practice Guidelines (CPGs) easier to use in oncologists’ routine clinical practice and support optimal decision-making in a rapidly evolving medical field
The European Society for Medical Oncology (ESMO) has announced today that the 2023 ESMO Breast Cancer Award is bestowed to Sara A. Hurvitz for her remarkable contributions to breast cancer clinical and laboratory-based research
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced today that the 2023 Heine H. Hansen Award is conferred on Paul Baas for his outstanding contribution to thoracic oncology research
ESMO has announced today that the 2023 ESMO TAT Honorary Award is presented to Susan Bates
ESMO is pleased to announce that the nomination process for the 2023 ESMO Society Awards is now open.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
ESMO renews its support to World Cancer Day (WCD) joining the #CloseTheCareGap campaign led by the Union for International Cancer Control (UICC).
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
From ASCO 2023 Annual Meeting:
Vorasidenib extends progression-free survival and delays the requirement for further intervention in patients with IDH-mutant WHO grade 2 diffuse glioma
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Netherlands
Spain
Switzerland
Portugal
Switzerland
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
